Open Access

Downregulation of miR‑3934‑5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1

  • Authors:
    • Aijun Ren
    • Zhenzhen Wen
    • Liangjie Zheng
  • View Affiliations

  • Published online on: July 1, 2019     https://doi.org/10.3892/etm.2019.7718
  • Pages: 1653-1660
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor protein p53‑inducible nuclear protein 1 (TP53INP1) is a tumor suppressor associated with malignant tumor metastasis. In addition, it has been reported that hsa‑microRNA (miR)‑3934 serves key roles in various types of lung cancer, including small‑cell lung carcinomas (SCLC) and non‑SCLC (NSCLC). Therefore, the present study aimed to determine the effects of miR‑3934‑5p on cell proliferation and apoptosis, and on sensitivity to cisplatin (DDP). Reverse transcription‑quantitative polymerase chain reaction analysis and western blotting were conducted for the analysis of mRNA and protein expression, respectively. Furthermore, the target of miR‑3934‑5p was investigated using a luciferase reporter assay and apoptosis was analyzed by flow cytometry. The results demonstrated that miR‑3934‑5p was upregulated in NSCLC tissues and A549 cells. Increases in the half‑maximal inhibitory concentration (IC50) and the expression of miR‑3934‑5p were observed in the A549/DDP group. miR‑3934‑5p mimic promoted the expression of miR‑3934‑5p and the IC50 of the A549 cells. miR‑3934‑5p inhibitor downregulated miR‑3934‑5p and reduced the IC50 of A549/DDP cells. miR‑3934‑5p was revealed to target the 3'‑untranslated region of TP53INP1. The downregulation of miR‑3934‑5p significantly suppressed the proliferation and promoted the apoptosis of A549/DDP cells, which were reversed by transfection with TP53INP1 small interfering (si)RNA. The protein and mRNA expression levels of TP53INP1, B‑cell lymphoma 2 (Bcl‑2)‑associated‑X and p21 were significantly increased, whereas those of Bcl‑2 were significantly decreased in the miR‑3934‑5p inhibitor group, which was significantly reduced by TP53INP1 siRNA transfection. miR‑3934‑5p, as a tumor suppressor in NSCLC, may promote the sensitivity of cells to DDP by targeting TP53INP1, associated with the suppression of cell proliferation and promotion of apoptosis.

References

1 

Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S and Gil-Bazo I: KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol Cancer. 17:332018. View Article : Google Scholar : PubMed/NCBI

2 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI

4 

Peters BJM, Cramer-Vd Welle CM, Smit AAJ, Schramel FMNH and van de Garde EMW; Santeon NSCLC Study Group, : Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008–2012. Cancer Epidemiol. 51:1–6. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Martin P and Leighl NB: Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol. 9:405–414. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI

8 

Berindan-Neagoe I, Monroig Pdel C, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Mathe A, Scott RJ and Avery-Kiejda KA: miRNAs and other epigenetic changes as biomarkers in triple negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Hiew MSY, Cheng HP, Huang CJ, Chong KY, Cheong SK, Choo KB and Kamarul T: Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype. J Biomed Sci. 25:572018. View Article : Google Scholar : PubMed/NCBI

12 

Yerukala Sathipati S and Ho SY: Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci Rep. 7:75072017. View Article : Google Scholar : PubMed/NCBI

13 

Wang Y, Sun H, Zhang D, Fan D, Zhang Y, Dong X, Liu S, Yang Z, Ni C, Li Y, et al: TP53INP1 inhibits hypoxia-induced vasculogenic mimicry formation via the ROS/snail signalling axis in breast cancer. J Cell Mol Med. 22:3475–3488. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018. View Article : Google Scholar : PubMed/NCBI

15 

Saadi H, Seillier M and Carrier A: The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie. 118:44–50. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Liao D, Li T, Ye C, Zeng L, Li H, Pu X, Ding C, He Z and Huang GL: miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells. Exp Ther Med. 15:1712–1717. 2018.PubMed/NCBI

17 

Jiang PH, Motoo Y, Garcia S, Iovanna JL, Pébusque MJ and Sawabu N: Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol. 12:691–696. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Li Q, Han Y, Wang C, Shan S, Wang Y, Zhang J and Ren T: MicroRNA-125b promotes tumor metastasis through targeting tumor protein 53-induced nuclear protein 1 in patients with non-small-cell lung cancer. Cancer Cell Int. 15:842015. View Article : Google Scholar : PubMed/NCBI

19 

Qin J, Luo M, Qian H and Chen W: Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 538:342–347. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Luo Q, Gu S, Li Y and Zhang Z: Improving the expression of TP53INP1 in A549 cells enhances the sensitivity of cells to arsenic treatment. Wei Sheng Yan Jiu. 46:120–125. 2017.PubMed/NCBI

21 

Lan D, Wang L, He R, Ma J, Bin Y, Chi X, Chen G and Cai Z: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. Am J Transl Res. 10:1295–1309. 2018.PubMed/NCBI

22 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

23 

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U and Frötschl R: Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One. 12:e01810812017. View Article : Google Scholar : PubMed/NCBI

24 

Hong S, Li X, Zhao Y, Yang Q and Kong B: 53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells. Oncol Lett. 15:9917–9922. 2018.PubMed/NCBI

25 

Zhu Z: Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways. Oncol Lett. 15:8841–8846. 2018.PubMed/NCBI

26 

Qin Y, Zhou X, Huang C, Li L, Liu H, Liang N, Chen Y, Ma D, Han Z, Xu X, et al: Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. Gene. 675:278–284. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Campbell KJ and Tait SWG: Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8(pii): 1800022018. View Article : Google Scholar : PubMed/NCBI

28 

Zhang CM, Zhao J and Deng HY: MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci. 20:792013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ren, A., Wen, Z., & Zheng, L. (2019). Downregulation of miR‑3934‑5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1. Experimental and Therapeutic Medicine, 18, 1653-1660. https://doi.org/10.3892/etm.2019.7718
MLA
Ren, A., Wen, Z., Zheng, L."Downregulation of miR‑3934‑5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1". Experimental and Therapeutic Medicine 18.3 (2019): 1653-1660.
Chicago
Ren, A., Wen, Z., Zheng, L."Downregulation of miR‑3934‑5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1653-1660. https://doi.org/10.3892/etm.2019.7718